RhumbLine Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.6M | Sell |
516,786
-5,339
| -1% | -$292K | 0.02% | 571 |
|
|
2026
Q1 | $29.5M | Buy |
522,125
+8,877
| +2% | +$518K | 0.03% | 558 |
|
|
2025
Q4 | $30.5M | Sell |
513,248
-50,009
| -9% | -$2.72M | 0.02% | 547 |
|
|
2025
Q3 | $30.5M | Buy |
563,257
+500
| +0.1% | +$28.6K | 0.02% | 549 |
|
|
2025
Q2 | $30.9M | Buy |
562,757
+8,233
| +1% | +$485K | 0.03% | 530 |
|
|
2025
Q1 | $39.2M | Sell |
554,524
-1,731
| -0.3% | -$116K | 0.04% | 417 |
|
|
2024
Q4 | $36.6M | Buy |
556,255
+11,025
| +2% | +$738K | 0.03% | 438 |
|
|
2024
Q3 | $38.3M | Sell |
545,230
-6,323
| -1% | -$529K | 0.03% | 423 |
|
|
2024
Q2 | $45.4M | Buy |
551,553
+303,207
| +122% | +$25.2M | 0.04% | 355 |
|
|
2024
Q1 | $21.7M | Sell |
248,346
-1,497
| -0.6% | -$134K | 0.02% | 666 |
|
|
2023
Q4 | $24.1M | Buy |
249,843
+1,481
| +0.6% | +$131K | 0.03% | 572 |
|
|
2023
Q3 | $22M | Sell |
248,362
-3,477
| -1% | -$309K | 0.03% | 583 |
|
|
2023
Q2 | $21.8M | Buy |
251,839
+36,822
| +17% | +$3.47M | 0.02% | 606 |
|
|
2023
Q1 | $20.9M | Sell |
215,017
-4,878
| -2% | -$506K | 0.03% | 585 |
|
|
2022
Q4 | $22.8M | Buy |
219,895
+9,908
| +5% | +$930K | 0.03% | 527 |
|
|
2022
Q3 | $17.8M | Buy |
209,987
+17,315
| +9% | +$1.54M | 0.03% | 585 |
|
|
2022
Q2 | $16M | Buy |
192,672
+29,286
| +18% | +$2.33M | 0.02% | 647 |
|
|
2022
Q1 | $12.6M | Buy |
163,386
+7,373
| +5% | +$617K | 0.02% | 841 |
|
|
2021
Q4 | $13.8M | Buy |
156,013
+5,813
| +4% | +$480K | 0.02% | 801 |
|
|
2021
Q3 | $11.6M | Sell |
150,200
-13,392
| -8% | -$1.06M | 0.02% | 869 |
|
|
2021
Q2 | $13.7M | Sell |
163,592
-28,595
| -15% | -$2.27M | 0.02% | 821 |
|
|
2021
Q1 | $14.5M | Sell |
192,187
-11,910
| -6% | -$973K | 0.02% | 765 |
|
|
2020
Q4 | $17.9M | Sell |
204,097
-11,643
| -5% | -$923K | 0.02% | 598 |
|
|
2020
Q3 | $16.4M | Sell |
215,740
-14,933
| -6% | -$1.51M | 0.03% | 559 |
|
|
2020
Q2 | $28.5M | Buy |
230,673
+43,446
| +23% | +$4.32M | 0.05% | 349 |
|
|
2020
Q1 | $15.8M | Buy |
187,227
+719
| +0.4% | +$62K | 0.03% | 466 |
|
|
2019
Q4 | $15.8M | Buy |
186,508
+5,729
| +3% | +$433K | 0.03% | 594 |
|
|
2019
Q3 | $12.2M | Sell |
180,779
-969
| -0.5% | -$74.6K | 0.02% | 677 |
|
|
2019
Q2 | $15.6M | Buy |
181,748
+2,539
| +1% | +$217K | 0.03% | 547 |
|
|
2019
Q1 | $15.9M | Sell |
179,209
-1,702
| -0.9% | -$158K | 0.03% | 533 |
|
|
2018
Q4 | $15.4M | Sell |
180,911
-9,378
| -5% | -$892K | 0.03% | 526 |
|
|
2018
Q3 | $18.5M | Sell |
190,289
-3,964
| -2% | -$396K | 0.04% | 467 |
|
|
2018
Q2 | $18.3M | Sell |
194,253
-8,040
| -4% | -$704K | 0.04% | 461 |
|
|
2018
Q1 | $16.4M | Sell |
202,293
-6,223
| -3% | -$534K | 0.03% | 491 |
|
|
2017
Q4 | $18.6M | Sell |
208,516
-1,548
| -0.7% | -$135K | 0.04% | 468 |
|
|
2017
Q3 | $19.6M | Sell |
210,064
-4,888
| -2% | -$432K | 0.04% | 436 |
|
|
2017
Q2 | $19.5M | Sell |
214,952
-2,841
| -1% | -$258K | 0.04% | 420 |
|
|
2017
Q1 | $19.1M | Buy |
217,793
+7,857
| +4% | +$699K | 0.04% | 423 |
|
|
2016
Q4 | $17.4M | Buy |
209,936
+26,477
| +14% | +$2.28M | 0.04% | 423 |
|
|
2016
Q3 | $17M | Buy |
183,459
+13,889
| +8% | +$1.31M | 0.05% | 389 |
|
|
2016
Q2 | $13.2M | Buy |
169,570
+12,089
| +8% | +$1.03M | 0.04% | 443 |
|
|
2016
Q1 | $13M | Sell |
157,481
-765
| -0.5% | -$62.2K | 0.04% | 425 |
|
|
2015
Q4 | $16.6M | Buy |
158,246
+1,550
| +1% | +$162K | 0.05% | 346 |
|
|
2015
Q3 | $16.5M | Buy |
156,696
+5,211
| +3% | +$696K | 0.06% | 336 |
|
|
2015
Q2 | $20.7M | Buy |
151,485
+16,941
| +13% | +$2.1M | 0.07% | 294 |
|
|
2015
Q1 | $16.8M | Buy |
134,544
+9,836
| +8% | +$1.04M | 0.05% | 354 |
|
|
2014
Q4 | $11.3M | Sell |
124,708
-435
| -0.3% | -$36.2K | 0.03% | 455 |
|
|
2014
Q3 | $9.03M | Sell |
125,143
-7,243
| -5% | -$476K | 0.03% | 504 |
|
|
2014
Q2 | $8.24M | Buy |
132,386
+12,583
| +11% | +$760K | 0.02% | 559 |
|
|
2014
Q1 | $8.17M | Sell |
119,803
-5,266
| -4% | -$388K | 0.02% | 579 |
|
|
2013
Q4 | $8.79M | Sell |
125,069
-10,338
| -8% | -$702K | 0.03% | 541 |
|
|
2013
Q3 | $9.78M | Sell |
135,407
-1,057
| -0.8% | -$70.2K | 0.03% | 493 |
|
|
2013
Q2 | $7.61M | Buy |
+136,464
| New | +$8.5M | 0.02% | 576 |
|
Other funds holding BMRN
VPC
RhumbLine Advisers's BMRN Position: Q2 2026 in Review
RhumbLine Advisers reduced its BioMarin Pharmaceuticals (BMRN) stake by 1% in Q2 2026, selling an estimated $292K and leaving 516,786 shares worth $29.6M. The position accounts for 0.02% of the portfolio, ranked #571.
RhumbLine Advisers first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $45.4M in Q2 2024. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- RhumbLine Advisers held 516,786 shares of BioMarin Pharmaceuticals worth $29.6M as of Q2 2026.
- RhumbLine Advisers sold 5,339 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $292K.
- BioMarin Pharmaceuticals made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #571 holding.
- RhumbLine Advisers first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's BioMarin Pharmaceuticals position peaked at $45.4M in Q2 2024.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.